journal
Journals Critical Reviews in Oncology/h...

Critical Reviews in Oncology/hematology

https://read.qxmd.com/read/38527594/tertiary-prevention-strategies-for-micrometastatic-lymph-node-cervical-cancer-a-systematic-review-and-a-prototype-of-an-adapted-model-of-care
#1
REVIEW
Marcin Śniadecki, Benedetta Guani, Paulina Jaworek, Dagmara Klasa-Mazurkiewicz, Katia Mahiou, Karolina Mosakowska, Alessandro Buda, Patryk Poniewierza, Olga Piątek, Adrien Crestani, Maria Stasiak, Vincent Balaya, Oliwia Musielak, Luiza Piłat, Karolina Maliszewska, Cynthia Aristei, Paweł Guzik, Szymon Wojtylak, Marcin Liro, Thomas Gaillard, Roman Kocian, Anna Gołąbiewska, Zuzanna Chmielewska, Dariusz Wydra
PURPOSE: We found a need for balancing the application of clinical guidelines and tailored approaches to follow-up of cervical cancer (CC) patients in the lymph node micrometastatic (MICs) setting. This review aimed to determine the current knowledge of management of MIC-positive CC cases. METHODOLOGY: We addressed prognostic and risk of recurrence monitoring impacts associated with MIC+ cases. The electronic databases for literature and relevant articles were analysed...
March 23, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38521284/emerge-of-colorectal-cancer-in-lynch-syndrome-despite-colonoscopy-surveillance-a-challenge-of-hide-and-seek
#2
REVIEW
Noah C Helderman, Monique E van Leerdam, Matthias Kloor, Aysel Ahadova, Maartje Nielsen
Even with colonoscopy surveillance, Lynch syndromes (LS) carriers still develop colorectal cancer (CRC). The cumulative incidence of CRCs under colonoscopy surveillance varies depending on the affected mismatch repair (MMR) gene. However, the precise mechanisms driving these epidemiological patterns remain incompletely understood. In recent years, several potential mechanisms explaining the occurrence of CRCs during colonoscopy surveillance have been proposed in individuals with and without LS. These encompass biological factors like concealed/accelerated carcinogenesis through a bypassed adenoma stage and accelerated progression from adenomas...
March 21, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38492760/vascular-access-device-type-for-systemic-anti-cancer-therapies-in-cancer-patients-a-scoping-review
#3
REVIEW
C Duggan, O Hernon, R Dunne, V McInerney, S R Walsh, A Lowery, M McCarthy, P J Carr
BACKGROUND: Patients with cancer can expect to receive numerous invasive vascular access procedures for intravenous therapy and clinical diagnostics. Due to the increased incidence and prevalence of cancer globally there will be significantly more people who require first-line intravenous chemotherapy over the next ten years. METHODS: Our objective was to determine the types of evidence that exist for the vascular access device (VAD) type for the delivery of systemic anti-cancer therapy (SACT) in cancer patients...
March 14, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38490281/gut-and-local-microbiota-in-patients-with-cancer-increasing-evidence-and-potential-clinical-applications
#4
REVIEW
Anna Amela Valsecchi, Giorgia Ferrari, Chiara Paratore, Rossana Dionisio, Francesca Vignani, Paola Sperone, Giorgio Vellani, Silvia Novello, Massimo Di Maio
In recent years, cancer research has highlighted the role of disrupted microbiota in carcinogenesis and cancer recurrence. However, microbiota may also interfere with drug metabolism, influencing the efficacy of cancer drugs, especially immunotherapy, and modulating the onset of adverse events. Intestinal micro-organisms can be altered by external factors, such as use of antibiotics, proton pump inhibitors treatment, lifestyle and the use of prebiotics or probiotics. The aim of our review is to provide a picture of the current evidence about preclinical and clinical data of the role of gut and local microbiota in malignancies and its potential clinical role in cancer treatments...
March 13, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38484899/effect-of-non-pharmacological-interventions-on-symptoms-and-quality-of-life-in-patients-with-hematological-malignancies-a-systematic-review
#5
REVIEW
Maja Pedersen, Mette Schaufuss Engedal, Anders Tolver, Maria Torp Larsen, Brian Thomas Kornblit, Kirsten Lomborg, Mary Jarden
BACKGROUND: Non-pharmacological interventions have the potential to enhance health-related quality of life (HRQoL) through symptom management. This systematic review aims to identify, collate, and assess randomized controlled trials investigating the effect of non-pharmacological interventions on symptoms and HRQoL within hematology. METHODS: MEDLINE/PUBMED, EMBASE, CINAHL, PSYCINFO and COCHRANE were searched up to April 2021. Outcomes were changes in symptoms and HRQoL...
March 12, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38479585/the-risk-of-breast-cancer-and-gynecologic-malignancies-after-ovarian-stimulation-meta-analysis-of-cohort-study
#6
REVIEW
Chuanju Chen, Hao Shi, Jingya Yang, Xiao Bao, Yingpu Sun
The effects of ovarian stimulation on breast and gynecological tumor incidence remain controversial. Therefore, the aim of this meta-analysis was to study the risk of cancer in ovarian stimulation. Of the 22713 studies initially identified, 28 were eligible for inclusion. The results revealed that the impact of ovarian cancer (RR = 1.33, [1.05; 1.69]) and cervical cancer (RR = 0.67, [0.46; 0.97]) is significant among the overall effects. In subgroup analysis, in the nulliparous population (RR = 0.81 [0.68; 0...
March 11, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38479584/rethinking-treatment-paradigms-neoadjuvant-therapy-and-de-escalation-strategies-in-hpv-positive-head-and-neck-cancer
#7
REVIEW
Jenna Bouassaly, Naser Karimi, Luiz Paulo Kowalski, Kalil Sultanem, Moulay Alaoui-Jamali, Alex Mlyanarek, Marco Mascarella, Michael Hier, Nader Sadeghi, Sabrina Daniela da Silva
Head and neck cancer (HNC) is the 6th most common cancer across the world, with a particular increase in HNC associated with human papilloma virus (HPV) among younger populations. Historically, the standard treatment for this disease consisted of combined surgery and radiotherapy or curative platinum-based concurrent chemoradiotherapy, with associated long term and late toxicities. However, HPV-positive HNC is recognized as a unique cancer subtype, typically with improved clinical outcomes. As such, treatment de-escalation strategies have been widely researched to mitigate the adverse effects associated with the current standard of care without compromising efficacy...
March 11, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38462151/killing-two-birds-with-one-stone-abscopal-effect-mechanism-and-its-application-prospect-in-radiotherapy
#8
REVIEW
Boyi Yu, Yuting Gao, Jiaxin Li, Feifei Gao, Jiahao Zhang, Linjing Li, Xianglong Feng, Dashan Zuo, Xiaodong Jin, Weiqiang Chen, Qiang Li
Abscopal effects are characterized by the emergence of neoplasms in regions unrelated to the primary radiation therapy site, displaying a gradual attenuation or regression throughout the progression of radiation therapy, which have been of interest to scientists since Mole's proposal in 1953. The incidence of abscopal effects in radiation therapy is intricately linked to the immune system, with both innate and adaptive immune responses playing crucial roles. Biological factors impacting abscopal effects ultimately exert their influence on the intricate workings of the immune system...
March 9, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38462150/cyclin-dependent-kinase-2-cdk2-inhibitors-and-others-novel-cdk-inhibitors-cdki-in-breast-cancer-clinical-trials-current-impact-and-future-directions
#9
REVIEW
Riccardo Gerosa, Rita De Sanctis, Flavia Jacobs, Chiara Benvenuti, Mariangela Gaudio, Giuseppe Saltalamacchia, Rosalba Torrisi, Giovanna Masci, Chiara Miggiano, Francesco Agustoni, Paolo Pedrazzoli, Armando Santoro, Alberto Zambelli
Aberrant cyclin-dependent kinase 2 (CDK2) activation has been identified as a main resistance mechanism to CDK4/6 inhibition in hormone-receptor positive (HR+) breast cancer. Additionally, consistent preclinical evidence states its crucial role in MYC and CCNE1 overexpressed cancer survival, such as triple-negative breast cancers (TNBC), thus representing an appealing and relatively unexplored target treatment opportunity. Despite emerging initial results of novel CDK2 inhibitors (CDK2i) activity, a comprehensive outcomes collection is currently absent from the scientific literature...
March 8, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38462149/multi-disciplinary-management-of-esophageal-carcinoma-current-practices-and-future-directions
#10
REVIEW
Chanyoot Bandidwattanawong
Esophageal cancer in one of the most malignant and hard-to-treat cancers. Esophageal squamous carcinoma (ESCC) is most common in Asian countries, whereas adenocarcinoma at the esophago-gastric junction (EGJ AC) is more prevalent in the Western countries. Due to differences in both genetic background and response to chemotherapy and radiotherapy, both histologic subtypes need different paradigms of management. Since the landmark CROSS study has demonstrated the superior survival benefit of tri-modality including neoadjuvant chemoradiotherapy prior to esophagectomy, the tri-modality becomes the standard of care; however, it is suitable for a highly-selected patient...
March 8, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38462148/impact-of-smoking-cessation-duration-on-lung-cancer-mortality-a-systematic-review-and-meta-analysis
#11
REVIEW
Hongkun Lai, Quanzhen Liu, Qianxian Ye, Ziyang Liang, Zhiwei Long, Yinghong Hu, Qianlong Wu, Mei Jiang
BACKGROUND: Smoking history is a heterogeneous situation for different populations, and numerous studies suggest that smoking cessation is conducive to reduce the mortality of lung cancer. However, no quantitative meta-analysis regarding smoking cessation duration based on different populations has demonstrated it clearly. METHODS: We systematically searched four electronic databases (PubMed, Embase, the Cochrane Central Register of Controlled Trials, and Scoups) till February 2023...
March 8, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38460929/efficacy-of-immune-checkpoint-inhibitors-combinations-as-first-line-systemic-treatment-in-patients-with-advanced-urothelial-carcinoma-a-systematic-review-and-network-meta-analysis
#12
REVIEW
Fernando Sabino Marques Monteiro, Andrey Soares, Veronica Mollica, Caio Abner Leite, Andre Paterno Castello Dias Carneiro, Alessandro Rizzo, Maria T Bourlon, Andre Deeke Sasse, Matteo Santoni, Shilpa Gupta, Francesco Massari
BACKGROUND: Combinations of immune checkpoint inhibitors (ICI) with platinum-based chemotherapy (PlatinumCT) or with another ICI in the first-line setting for patients with metastatic urothelial carcinoma (mUC) have mixed results. METHODS: Records were searched electronically from January 2019 to January 2024. A meta-analysis was performed to evaluate OS, progression-free survival (PFS), and overall response rate (ORR). RESULTS: Immune-based combinations were associated with an OS (HR: 0...
March 7, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38460928/microbiome-and-lung-cancer-carcinogenic-mechanisms-early-cancer-diagnosis-and-promising-microbial-therapies
#13
REVIEW
Weici Liu, Zheshun Pi, Xiaokun Wang, Chenwei Shang, Chenghu Song, Ruixin Wang, Zhao He, Xu Zhang, Yuan Wan, Wenjun Mao
Microbiomes in the lung, gut, and oral cavity are correlated with lung cancer initiation and progression. While correlations have been preliminarily established in earlier studies, delving into microbe-mediated carcinogenic mechanisms will extend our understanding from correlation to causation. Building upon the causative relationships between microbiome and lung cancer, a novel concept of microbial biomarkers has emerged, mainly encompassing cancer-specific bacteria and circulating microbiome DNA. They might function as noninvasive liquid biopsy techniques for lung cancer early detection...
March 7, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38460927/physical-activity-for-cancer-prehabilitation-a-scoping-review
#14
REVIEW
Lin Yang, Azam Alice, Christine M Friedenreich
This scoping review aims to synthesize the current landscape of physical activity in cancer prehabilitation and identify knowledge gaps. We searched MEDLINE, EMBASE, SCOPUS and WEB OF SCIENCE for exercise interventions and observational studies that measured exercise or physical activity before cancer treatment from inception to January 20, 2023. Fifty-one articles from 44 unique studies were reviewed, including 32 intervention and 12 observational studies. Surgery is the only treatment modality that has been investigated...
March 7, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38447785/the-association-between-paraneoplastic-neurological-syndromes-pns-and-urothelial-carcinoma-a-review-of-the-literature
#15
REVIEW
Sarafina Urenna Otis, Giuseppe Luigi Banna, Akash Maniam
Paraneoplastic neurological syndromes (PNS) are rare neurological disorders arising from malignancy-triggered autoimmunity, yet their association with urothelial carcinoma remains unclear. This systematic review intends to explore any connection, alongside patient/clinical features and management. A literature search identified 25 cases of bladder and upper tract carcinoma linked to PNS. Overall, while infrequent, a meaningful association between PNS and urothelial carcinoma was found in that 84% of cases met a 'possible'-or-'higher-likelihood' PNS diagnosis...
March 4, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38442809/efficacy-and-safety-of-trastuzumab-deruxtecan-in-treating-human-epidermal-growth-factor-receptor-2-low-positive-advanced-breast-cancer-a-meta-analysis-of-randomized-controlled-trials
#16
REVIEW
Rui Ma, Yixun Shi, Ruijuan Yan, Shiqing Yin, Huanen Bu, Jie Huang
BACKGROUND: A novel antibody-drug conjugate, trastuzumab deruxtecan is a combination of a human epidermal growth factor receptor 2 (HER2)-targeting antibody and DNA topoisomerase I inhibitor used to treat HER2-low/positive advanced breast cancer. To determine its safety and efficacy in treating HER2-low/positive advanced breast cancer, we performed a meta-analysis of several randomized clinical trials (RCTs) including DESTINY-Breast02 (NCT03523585), DESTINY-Breast03 (NCT03529110), and DESTINY-Breast04 (NCT03734029)...
March 3, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38442808/the-cytokines-in-tumor-microenvironment-from-cancer-initiation-elongation-progression-to-metastatic-outgrowth
#17
REVIEW
Rajalaxmi Pradhan, Anushka Kundu, Chanakya Nath Kundu
It is a well-known fact that cancer can be augmented by infections and inflammation. In fact, chronic inflammation establishes a tumor-supporting-microenvironment (TME), which contributes to neoplastic progression. Presently, extensive research is going on to establish the interrelationship between infection, inflammation, immune response, and cancer. Cytokines are the most essential components in this linkage, which are secreted by immune cells and stromal cells of TME. Cytokines have potential involvement in tumor initiation, elongation, progression, metastatic outgrowth, angiogenesis, and development of therapeutic resistance...
March 3, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38437908/immune-therapies-of-b-cell-acute-lymphoblastic-leukaemia-in-children-and-adults
#18
REVIEW
David Kegyes, Gabriel Ghiaur, Anamaria Bancos, Ciprian Tomuleasa, Robert Peter Gale
B-cell acute lymphoblastic leukaemia (B-cell ALL) is a common haematologic cancer in children and adults. About 10 percent of children and 50 percent of adults fail to achieve a histological complete remission or subsequently relapse despite current anti-leukaemia drug therapies and/or haematopoietic cell transplants. Several new immune therapies including monoclonal antibodies and chimeric antigen receptor (CAR)-T-cells are proved safe and effective in this setting. We review data on US Food and Drug Administration (FDA)-approved immune therapies for B-cell ALL in children and adults including blinatumomab, inotuzumab ozogamicin, tisagenlecleucel, and brexucabtagene autoleucel...
March 2, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38432444/neoadjuvant-therapy-in-renal-cell-carcinoma-with-tumor-thrombus-a-systematic-review-and-meta-analysis
#19
REVIEW
Liangyou Gu, Cheng Peng, Huaikang Li, Tongyu Jia, Xinran Chen, Hanfeng Wang, Songliang Du, Lu Tang, Qiyang Liang, Baojun Wang, Xin Ma, Xu Zhang
To evaluate the efficacy, feasibility and safety of neoadjuvant therapy (NAT) for renal cell carcinoma with tumor thrombus (RCC-TT) in terms of response, perioperative and oncological outcomes, and compare the results between neoadjuvant and non-neoadjuvant groups. Overall, 29 single-arm studies and 5 cohort studies were included. Of the 204 patients undergoing NAT, 16.2% were level I, 35.3% level II, 24.0% level III and 18.6% level IV thrombus. Most of patients underwent preoperative targeted therapy, immunotherapy-based combination therapy was applied in 5...
March 1, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38431241/mapping-the-research-landscape-of-hpv-positive-oropharyngeal-cancer-a-bibliometric-analysis
#20
REVIEW
Angela Ammirabile, Federico Mastroleo, Giulia Marvaso, Daniela Alterio, Ciro Franzese, Marta Scorsetti, Pierfrancesco Franco, Caterina Giannitto, Barbara Alicja Jereczek-Fossa
OBJECTIVE: The aim of the study is to evaluate the scientific interest, the collaboration patterns and the emerging trends regarding HPV+ OPSCC diagnosis and treatment. MATERIALS AND METHODS: A cross-sectional bibliometric analysis of articles reporting on HPV+ OPSCC within Scopus database was performed and all documents published up to December 31th, 2022 were eligible for analysis. Outcomes included the exploration of key characteristics (number of manuscripts published per year, growth rate, top productive countries, most highly cited papers, and the most well-represented journals), collaboration parameters (international collaboration ratio and networks, co-occurrence networks), keywords analysis (trend topics, factorial analysis)...
March 1, 2024: Critical Reviews in Oncology/hematology
journal
journal
20089
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.